Jaguar Health Complies with Nasdaq Bid Price - June 26, 2024

SAN FRANCISCO, CA – Jaguar Health (NASDAQ:JAGX) revealed on June 26, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by The Nasdaq Stock Market LLC on June 25, 2024. This milestone ensures that JAGX's securities will continue to be listed and traded on Nasdaq.

"We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company," stated Lisa Conte, president and CEO of Jaguar Health. Conte further mentioned that an investor webcast, scheduled on or before July 23, 2024, will provide updates on Jaguar’s cancer supportive care portfolio. The event will feature insights from Jaguar's scientific team, patient advocates, and leading oncology experts discussing two prevalent and severe side effects of cancer therapy: cancer therapy-related diarrhea (CTD) and oral mucositis.

Jaguar Health, Inc. operates as a commercial-stage pharmaceutical company dedicated to developing innovative, plant-derived prescription medicines for both humans and animals suffering from gastrointestinal distress. Their focus includes addressing symptoms like chronic diarrhea, bowel urgency, incontinence, and cramping pain. 

Napo Pharmaceuticals, a subsidiary of Jaguar Health, specializes in creating and marketing prescription drugs that provide essential supportive care for neglected gastrointestinal symptoms across various complex diseases. Napo’s flagship product, crofelemer, is FDA-approved under the brand name Mytesi® for relieving noninfectious diarrhea in adults with HIV/AIDS undergoing antiretroviral therapy. Furthermore, crofelemer is currently being evaluated in Napo’s phase 3 OnTarget clinical trial aimed at preventing CTD.

Another significant arm of Jaguar Health is Napo Therapeutics, an Italian firm established in Milan in 2021. This entity aims to broaden crofelemer’s availability in Europe, particularly for orphan and rare diseases. Jaguar Animal Health, a trade name under Jaguar, focuses on developing gastrointestinal care solutions for animals.

Additionally, Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health Corp., emerged from Jaguar's Entheogen Therapeutics Initiative (ETI). It is dedicated to developing novel prescription medicines derived from plants for mental health conditions.

This announcement underscores Jaguar Health's commitment to advancing its portfolio and ensuring the continuous development and availability of its critical care solutions. With the upcoming webcast and anticipated phase 3 clinical trial results, the company is poised to make significant contributions to cancer supportive care, particularly in managing the debilitating side effects of cancer treatments. The successful compliance with Nasdaq regulations further solidifies Jaguar’s financial stability and market presence, allowing it to continue its mission of innovative healthcare solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!